Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Oncology
Filter     Order     Display # 
Date Item Title Hits
12 Mar 2010 FDA Allows IND for Bio-Path Holdings' Liposomal Grb-2 6
12 Mar 2010 Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer 8
12 Mar 2010 FDA Approves Five-Day Dosing Regimen for Dacogen 19
11 Mar 2010 BioSante Announces Positive Leukemia Vaccine Results 6
11 Mar 2010 Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer 6
11 Mar 2010 Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint 5
11 Mar 2010 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5
11 Mar 2010 FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5
11 Mar 2010 Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results 4
10 Mar 2010 ImmunoCellular Therapeutics’ Dendritic Cell-Based Vaccine Demonstrates Statistically Significant Increase in Survival in an Animal Model of Glioblastoma 4
10 Mar 2010 TRANSGENE SIGNS AN EXCLUSIVE OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ITS IMMUNOTHERAPY PRODUCT TG4010 5
09 Mar 2010 Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies 4
09 Mar 2010 Bavarian Nordic Successfully Completes End of Phase II Meeting for PROSTVAC 4
08 Mar 2010 Argos Therapeutics Presents Positive Phase 2 Data of its Arcelis™ Personalized Immunotherapy Platform in Metastatic RCC at ASCO GU Symposium 5
08 Mar 2010 Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients 7
08 Mar 2010 Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute for Development of Further Next-Generation Class II-Selective HDAC Inhibitor Compounds 6
08 Mar 2010 RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer 6
08 Mar 2010 Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer Treatment Apoptone to Phase IIb 6
08 Mar 2010 Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU 5
08 Mar 2010 Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer 8
05 Mar 2010 MOLOGEN AG receives approval for clinical study with cancer drug MGN1703 6
05 Mar 2010 Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 7
04 Mar 2010 Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer 10
04 Mar 2010 Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer 12
04 Mar 2010 Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer 8
03 Mar 2010 New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases 8
03 Mar 2010 Endocyte Announces DSMB Supports Continuation of Phase 2 PRECEDENT Study 7
02 Mar 2010 TopoTarget Company Announcement TopoTarget announces the European divestiture of Savene® to SpePharm Holding, BV and reconfirms the focus to develop and commercialise Belinostat 8
02 Mar 2010 Synta Announces Elesclomol Clinical Development to Resume 6
01 Mar 2010 GTC Provides Update on TG20 Monoclonal Antibody Targeting CD20 9
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 3900

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics